

neo-adjuvant chemotherapy. To improve cosmetic outcome, oncoplastic techniques should be applied whenever possible to achieve best margin width, optimal breast shape and no dead space to minimize boost dose volume; all to improve cosmetic outcome and diminish late side effects. In case mastectomy is indicated (either for oncological reasons or the wish of the patient), immediate breast shape reconstruction according to the form of the breast, the body shape of the patient or her desires, should be discussed and applied whenever possible.

Another option to diminish side-effects is the possibility of minimal invasive ablative surgery by radiofrequency ablation. So far, the disadvantage of this procedure is the lack of sufficient tumor tissue to stage the tumor and to estimate the extent of the tumor with great certainty. Further follow-up after necrotizing the tumor will be difficult since necrotic tissue will be in place for a long time.

All this requires an experienced breast surgeon who applies his/her technical skills only after multidisciplinary consultation and discussion of every individual patient.

Thursday, 25 March 2010

15:30–17:00

CLINICAL SCIENCE SYMPOSIUM

Is tailored chemotherapy becoming a reality?

209

Invited

Can we select patients for adjuvant therapy based on the presence of micro-metastatic disease?

C. Oakman¹. ¹Hospital of Prato, Medical Oncology, Prato, Italy

Adjuvant therapy targets minimal residual disease. However, the presence of minimal residual disease is presumed not measured. Our current approach for determining adjuvant systemic therapy is to assess the primary tumour, using traditional clinicopathological features or multigene signatures, and estimate an individual's recurrence risk. Subsequent treatment decisions are based on characteristics of the primary tumour (eg. ER, HER2) with the presumption of biological homogeneity between the primary lesion and micrometastases. However, biological discrepancy between a primary tumour and corresponding micrometastases may have significant therapeutic consequences.

An alternative approach is to identify micrometastatic disease postoperatively. Disseminated tumour cells (DTC) in the bone marrow and circulating tumour cells (CTC) from peripheral blood collection may offer quantification and biocharacterisation of residual disease. Detection at the single cell level with high sensitivity and specificity is facilitated by immunocytochemical and molecular enrichment assays. Detection of DTC at the time of surgery for the primary tumour is not currently a routine procedure. Standardised DTC detection and implementation in clinical trials are required. CTCs offer a less invasive potential alternative. New tools, such as a recently described anti-EpCAM and flow based microchip technology, 'CTC-chip', offer greater efficiency in cell capture. The biological role and clinical significance of CTC in early breast cancer remain unclear.

Some CTC and DTC remain dormant with patients never developing overt metastases. Detection of micrometastatic disease alone may not be enough. Favourable host features, including conducive stromal microenvironment and evasion of host immunity, appear critical for the switch from this dormant state to evolution of metastatic disease. New tools are required to assess this dynamic multifactorial interaction between tumour and host. A potential novel tool may be metabolomics, a science of metabolites and small molecules. As metabolomic analysis of systemic biofluids incorporates both tumour and host signal, a dynamic portrait of metabolic status may identify individuals at risk of relapse due to presence of both residual disease and favourable host features.

210

Invited

Anthracyclines and topoisomerase II alpha – what is beyond?

C. Desmedt¹, M. Piccart¹, C. Sotiriou¹. ¹Institut Jules Bordet, Medical Oncology, Brussels, Belgium

Anthracycline-based regimens are among the most active chemotherapies in breast cancer (BC). However, their use is associated with rare but significant toxicities and their efficacy may be restricted to a subset of BC patients. Topoisomerase IIa (TOP2A) is arguably a promising marker for predicting the efficacy of anthracycline-based chemotherapy for BC patients. However, several groups have reported conflicting results with regard to its predictive value.

We recently reported the results of the first neo-adjuvant trial – called TOP (NCT00162812) – designed to prospectively evaluate the predictive value of TOP2A and to identify biomarkers of response/resistance to anthracyclines. This trial was specifically designed to identify markers of efficacy to preoperative single-agent epirubicin (100 mg/m² q2 or q3wks) in 149 estrogen receptor (ER)-negative patients.

The results support TOP2A gene amplification, but not protein overexpression, as predictive marker of pathological complete response (pCR). However, it has recently been suggested that TOP2A might actually be a surrogate for CEP17 since an increased CEP17 copy number predicts for enhanced benefit of anthracyclines compared to CMF (Bartlett et al. *Cancer Res* 2009). Increased CEP17 was evident in 68% of the TOP trial cases. Interestingly, samples with TOP2A aberrations had a higher proportion of increased CEP17 than TOP2A normal samples but CEP17 status was not associated with pCR.

We further hypothesized that TOP2A gene amplification might be a surrogate for other genes that are co-amplified with TOP2A. To this end, we built and validated a TOP2A index that was made of genes located close to TOP2A.

Next, we investigated the predictive value of the biological gene expression modules (Desmedt et al. *Clin Can Res* 2008). We found that high levels of the tumor invasion module were associated with the presence of residual disease. This observation is consistent with the results reported recently by Farmer et al. (*Nat Med* 2009), which demonstrated that their stroma-related gene signature predicts resistance to neoadjuvant anthracycline-based chemotherapy. We also showed that high levels of the immune response module were associated with increased pCR rate.

Altogether, these results suggest that sensitivity to anthracyclines is likely multifactorial and that the cohort of patients who derive the largest benefit is not necessarily confined to the HER2/TOP2A co-amplified subgroup.

211

Invited

Predictive signatures for chemosensitivity and new targeted therapies – dream or reality?

H. Bonnefoi¹. ¹Institut Bergonié, Department of medical oncology University of Bordeaux 2, Bordeaux, France

To date, predictive markers have been analyzed either as single markers (for example, proliferation markers, hormone receptors, HER2 and p53) or in groups, commonly referred to as gene signatures, metagenes, multigene biomarkers, multigene predictors or multigene classifiers. I will concentrate in my lecture on signatures and address an important practical question: are these signatures ready for routine clinical use?

1. Predictive signatures for chemosensitivity [1]: They must address two questions: (a) which tumours are more likely to respond to chemotherapy? (b) what is the optimal chemotherapy regimen for a specific tumour or group of tumours? The signatures which answer these questions are likely to be different; for the sake of simplicity I will describe them in two categories: those predicting general chemosensitivity (meaning that a tumour is sensitive to any chemotherapy or to a wide range of chemotherapeutic drugs) and those predicting drug-specific chemosensitivity (meaning that a tumour is sensitive to a specific class of agents). I will review retrospective trials that have reported promising chemotherapy signatures, presenting in a comprehensive manner for the non bio-informatician the different methods used so far.

2. Signatures for targeted therapies (oncogenic pathways signatures [2]): I will briefly explain how these signatures have been identified and discuss the value of DNA based and RNA based techniques.

3. Integrated approach [3]: Unsupervised gene expression analyses have allowed to develop a molecular classification of breast cancer and to identify at least 5 subtypes (Luminal A, Luminal B, HER2 enriched, Basal and normal like). A group has tried to further dissect this classification using oncogenic and chemosensitivity signatures. Concentrating on the Luminal B and Basal subtypes, they found a high variability of specific oncogenic pathways (MYC, E2F3, SRC) within these subtypes. Similarly they found a clear heterogeneity of chemosensitivity signatures within these two subtypes. These findings may have important implications when designing a trial tailoring the treatment based on oncogenic pathways and/or chemosensitivity signatures.

In addition, I will briefly summarize prospective trials (either ongoing or under development). Of note, these trials will be presented and discussed in more details in my Friday lecture "Incorporating multigene signatures into the design of adjuvant clinical trials".

References

- [1] Bonnefoi H, Underhill C, Iggo R, Cameron D. Predictive signatures for chemotherapy sensitivity in breast cancer: Are they ready for use in the clinic? *Eur J Cancer* 2009; 45(10): 1733–43.
- [2] Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. *Nature* 2006; 439(7074): 353–7.

- [3] Bild AH, Parker JS, Gustafson AM, Acharya CR, Hoadley KA, Anders C, et al. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. *Breast Cancer Res* 2009; 11(4): R55.

212

Invited

Targeting DNA repair deficiency

A. Tutt¹. ¹King's College London, Breakthrough Breast Cancer Research Unit Research Oncology Guy's Hospital, London, United Kingdom

Epithelial carcinomas are in general diseases occurring as a result of the acquisition of and selection for multiple mutations in a parental somatic cell clone in the tissues of the primary site. In the last two decades the role of genome caretakers, which function in key areas of the DNA damage response, have been recognized as important tumour suppressor genes. Inactivating mutations in these genes occur as germline and/or as somatic mutations. In either event, loss of function in a tumour cell pre-cursor clone leads to accelerated mutation acquisition and underpins the etiology of the tumour. As an understanding of the complex network that is the DNA damage response matures additional roles for signaling pathways, already recognized to be central to the establishment of the cancer phenotype, as controllers of DNA repair are being discovered. This has relevance to identification of wider populations susceptible to approaches that target DNA repair deficiency. Many established cancer chemotherapeutics exert their effect by creating DNA damage that has some selectivity for tumour cells. How populations of patients respond to these agents at common tumour primary sites have been explored in recent trials. The nature of some of these analyses will be explored in epithelial cancers and breast cancers specifically. More recently the development of targeted therapies, such as PARP inhibitors, that can target deficiencies in DNA repair have been described. The results of the first trials that explore these approaches, based on the concept of synthetic lethality, are emerging and will be reviewed. In contrast to the role of some tumour suppressor genes and oncogenes, continued loss of function of genome caretakers may not confer continuing selective tumour survival advantage after the establishment of the fully malignant phenotype. Indeed a selective pressure may exist for regain of DNA repair functions during DNA damaging therapy. The rationale, pre-clinical and clinical evidence for these potential resistance mechanisms will be reviewed.

213

Proffered paper oral

Duplication of chromosome 17 CEP predicts for anthracycline benefit: evidence from an international meta-analysis of 4 adjuvant breast cancer trials for the HER2/TOP2A meta-analysis study group

J.M.S. Bartlett¹, A. Munro¹, F.P. O'Malley², H. Earl³, C.J. Poole⁴, F. Cardoso⁵, C.J. Twelves⁶, K.I. Pritchard⁷, D.W. Rea⁸, A. Di Leo⁹.

¹Edinburgh Cancer Research Centre, Pathology, Edinburgh, United Kingdom; ²University of Toronto, Pathology, Toronto, Canada; ³University of Cambridge, Medical Oncology, Cambridge, United Kingdom; ⁴University of Warwick, Medical Oncology, Warwick, United Kingdom; ⁵Institut Jules Bordet, Medical Oncology, Brussels, Belgium; ⁶University of Leeds, Medical Oncology, Leeds, United Kingdom; ⁷NCIC CTG, Medical Oncology, Toronto, Canada; ⁸University of Birmingham, Medical Oncology, Birmingham, United Kingdom; ⁹University di Prato, Medical Oncology, Prato, Italy

Background: Evidence for *HER2/TOP2A* as predictive biomarkers of anthracycline response is conflicting. An interim meta-analysis (Di Leo *et al Cancer Res*;69:99S) suggested a weak, but statistically significant, association between *TOP2A* and anthracycline benefit. We have previously shown that duplication of chromosome 17 alpha satellite (CEP17) predicts sensitivity to anthracyclines [1,2]. We have now performed a retrospective meta-analysis, incorporating data from 4 trials (BR9601, NEAT, MA.5 and the Belgian study), to test the hypothesis that CEP17 duplication is a predictive biomarker for anthracycline benefit and provide a unifying hypothesis for previous conflicting data.

Methods: FISH was performed in 2 laboratories (Bartlett for BR9601/NEAT & Belgian studies & O'Malley for MA5). ER/PgR (IHC) etc were collected from trial Case Report Forms. BR9601/NEAT & Belgian study tumors were scored counting all cells with a minimum of one CEP17 signal/cell: in MA.5 a minimum of 2 CEP17 signals were required for cells to be scored. These methodological differences did not affect *HER2/CEP17* ratios but necessitated different definitions for CEP17 duplication defined as >1.86 observed copies/cell for BR9601, NEAT and Belgian [3] and >2.25 for MA.5 [4].

Results: FISH was successful in 85% (2531/2975) of cases. CEP17 duplication was detected in 27.5% of tumors (BR9601=37.6%, NEAT=20.0%, MA5=40.2% & Belgian=28.5%) and was associated with poorer OS &

RFS (HR 1.27, 95% CI 0.10–1.47, $p=0.018$ & HR 1.25 95% CI 1.09–1.43 $p=0.011$, respectively).

A significant treatment by marker interaction (CEP17) was observed in a meta-analysis of all data (2531 cases) as univariate ($p<0.005$) & multivariate regression analyses (adjusted for treatment, grade, size, ER, nodes CEP17, CEP17-by-treatment & HER2) Recurrence free survival (RFS) hazard ratio (HR) was 1.67 (95% CI 1.25–2.22, $p=0.0006$) and overall survival (OS) HR was 1.63 (95% CI 1.18–2.22, $p=0.003$). In the two largest studies, NEAT ($n=1462$) and MA5 ($n=622$), this treatment by marker interaction (CEP17) was significant for RFS ($p<0.05$) and in all other analyses non-significant trends for OS & RFS were seen. (Trial specific HRs with 95% CIs RFS: 0.73 (0.32–1.79), 0.56 (0.34–0.93), 0.62 (0.39–0.98) & 0.59 (0.15–2.33), OS: 0.74 (0.30–1.85), 0.61 (0.36–1.04), 0.60 (0.35–1.01) & 0.49 (0.10–2.33); BR9601, NEAT, MA5 & Belgian respectively) analyses. HER2 (all 4 trials) and TOP2A (NEAT/BR9601) did not show any significant interactions.

Conclusions: Meta-analysis of 4 adjuvant breast cancer trials shows a highly significant treatment by marker effect for CEP17 duplication as a predictor of anthracycline benefit for both RFS and OS in univariate and multivariate regression analyses. CEP17 duplication may reflect either chromosomal instability or polyploidy and further analysis will explore the underlying mechanisms for this effect. CEP17 is readily assessed in ISH analysis of HER2 status and may represent a clinically useful biomarker for selection of patients likely to benefit from anthracycline containing chemotherapies.

References

- [1] Bartlett *et al Cancer Res* 69:74S.
- [2] Bartlett *et al Cancer Res* 69:364S.
- [3] Watters BCRT 2003 77:109–14.
- [4] Goetz 2004.

Thursday, 25 March 2010

15:30–17:00

CLINICAL SCIENCE SYMPOSIUM

Lobular cancer is different

214

Invited

Distinct pathological characteristics of lobular carcinoma

S.R. Lakhani¹, P.T. Simpson¹. ¹UQ Centre for Clinical Research, Molecular & Cellular Pathology, Brisbane, Australia

The recognition and diagnosis of morphological variants is critical to stratifying breast cancer into clinically meaningful subgroups and to develop an understanding of the biological nature and the clinical significance of such entities.

Classic lobular carcinomas (CLC) account for 10% to 15% of all breast cancers. It has a very distinct morphology with small cells growing in single files or small aggregates and with a discohesive pattern. At the molecular level, CLCs show recurrent physical loss of chromosome 16q together with the lack of E-cadherin (CDH1 gene) expression. A number of variants have also been described including alveolar, solid and pleomorphic subtypes.

Pleomorphic lobular carcinomas (PLC) of the breast display histological features associated with classic invasive lobular carcinoma (ILC), yet they also exhibit more conspicuous nuclear atypia and pleomorphism, and an aggressive clinical behaviour. This subtype is rare (~1%) and was first described as a high-grade variant of the classic invasive lobular carcinoma (ILC). There has been some contention amongst pathologists as to whether PLC is indeed a discreet entity, a lobular variant or even a type of high grade IDC. The introduction of E-cadherin immunohistochemical staining into diagnostic practice to help differentiate lobular and ductal carcinomas, together with molecular genetic analysis has added support for PLC being a lobular variant. PLC is now becoming accepted as a clinically important tumour subtype with an aggressive phenotype and a poor prognosis.

Considerable progress has been made in understanding molecular biology using a variety of methodologies including comparative genomic hybridization (CGH), array CGH, expression profiling and sequencing. The morphological and molecular profiles of the classic and variant subtype, in particular the pleomorphic variant will be discussed.

215

Invited

Special aspects of local treatment for invasive lobular carcinoma

P. Poortmans¹. ¹Dr. Bernard Verbeeten Instituut, Radiotherapy, Tilburg, The Netherlands

Infiltrating lobular carcinoma (ILC) is known – as compared to other breast cancer types – for its multicentricity, its more diffuse growth pattern and the